PMID- 15721280
OWN - NLM
STAT- MEDLINE
DCOM- 20050413
LR  - 20121115
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 329
IP  - 1
DP  - 2005 Apr 1
TI  - Effect of matrix metalloproteinase inhibition on adipose tissue development.
PG  - 105-10
AB  - The effect of Ro 28-2653, a synthetic matrix metalloproteinase (MMP) inhibitor, 
      on adipose tissue development was studied in mice kept on a high fat diet (HFD). 
      Five-week-old male wild-type (C57Bl/6J) mice were fed the HFD (42% kcal as fat, 
      20.1 kJ/g) and received daily p.o. instillations of inhibitor (30 mg/kg) or 
      vehicle. After 15 weeks of the HFD, the body weight gain was lower in the 
      inhibitor-treated group (7.4 +/- 0.88 g versus 10 +/- 1.4 g) whereas the weights 
      of the isolated subcutaneous (SC) or gonadal (GON) fat deposits were 10-15% 
      lower. The number of adipocytes in adipose tissues of the inhibitor-treated mice 
      was somewhat higher (10-17%) but their diameter was smaller (about 10%). In situ 
      zymography showed reduced gelatinolytic activity in SC (about 2.7-fold) and GON 
      (1.4-fold) adipose tissue of inhibitor-treated mice, whereas their fibrillar 
      collagen content was higher (1.5- and 4.7-fold, respectively). In both SC and GON 
      adipose tissues of inhibitor-treated mice, MMP-2 (gelatinase A) and MMP-14 
      (membrane type-1 MMP) were 2- to 3-fold upregulated, whereas MMP-9 (gelatinase B) 
      mRNA levels were not affected. Thus, in this in vivo model partial inhibition of 
      gelatinolytic activity is associated with moderate effects on adipose tissue 
      development and cellularity. Possibly, enhanced MMP expression to some extent 
      counteracts the in vivo effect of the inhibitor in adipose tissue.
FAU - Demeulemeester, Diego
AU  - Demeulemeester D
AD  - Center for Molecular and Vascular Biology, University of Leuven, Belgium.
FAU - Collen, Desire
AU  - Collen D
FAU - Lijnen, H Roger
AU  - Lijnen HR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (DNA Primers)
RN  - 0 (Dietary Fats)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Matrix Metalloproteinase Inhibitors)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 0 (RNA, Messenger)
RN  - 0 (Ro 28-2653)
RN  - EC 3.4.24.- (Matrix Metalloproteinases, Membrane-Associated)
RN  - EC 3.4.24.- (Metalloendopeptidases)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Adipose Tissue/*growth & development/physiology
MH  - Animal Feed
MH  - Animals
MH  - Body Weight
MH  - DNA Primers/chemistry
MH  - Dietary Fats
MH  - Enzyme Inhibitors/*pharmacology
MH  - *Gene Expression Regulation
MH  - Male
MH  - Matrix Metalloproteinase 2/biosynthesis
MH  - Matrix Metalloproteinase 9/biosynthesis
MH  - *Matrix Metalloproteinase Inhibitors
MH  - Matrix Metalloproteinases, Membrane-Associated
MH  - Metalloendopeptidases/biosynthesis
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neovascularization, Physiologic
MH  - Obesity/genetics
MH  - Piperazines/pharmacology
MH  - Pyrimidines/pharmacology
MH  - RNA, Messenger/metabolism
MH  - Time Factors
EDAT- 2005/02/22 09:00
MHDA- 2005/04/14 09:00
CRDT- 2005/02/22 09:00
PHST- 2005/01/20 00:00 [received]
PHST- 2005/02/22 09:00 [pubmed]
PHST- 2005/04/14 09:00 [medline]
PHST- 2005/02/22 09:00 [entrez]
AID - S0006-291X(05)00164-6 [pii]
AID - 10.1016/j.bbrc.2005.01.103 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2005 Apr 1;329(1):105-10. doi: 
      10.1016/j.bbrc.2005.01.103.